Advertisement
Canada markets closed

  • S&P/TSX

    21,639.10
    -59.00 (-0.27%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CAD/USD

    0.7281
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     

  • Bitcoin CAD

    91,593.70
    +675.96 (+0.74%)
     

  • CMC Crypto 200

    1,382.86
    -35.01 (-2.47%)
     

  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     

  • RUSSELL 2000

    2,006.16
    -32.75 (-1.61%)
     

  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     

  • NASDAQ

    17,688.88
    +21.28 (+0.12%)
     

  • VOLATILITY

    12.66
    +0.72 (+6.03%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • NIKKEI 225

    38,814.56
    +94.06 (+0.24%)
     

  • CAD/EUR

    0.6798
    +0.0024 (+0.35%)
     

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

Zacks Equity Research
·2 min read

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why This 1 Growth Stock Should Be On Your Watchlist

For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time.

ADVERTISEMENT

United Therapeutics (UTHR)

Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use.

UTHR is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected to grow 22.2% year-over-year for the current fiscal year, with sales growth of 15.1%.

Six analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.88 to $24.20 per share. UTHR boasts an average earnings surprise of 12.4%.

On a historic basis, United Therapeutics has generated cash flow growth of 10.7%, and is expected to report cash flow expansion of 33.3% this year.

With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, UTHR should be on investors' short lists.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

United Therapeutics Corporation (UTHR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research